{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erenumab+Dose+1", "query": { "intervention": "Erenumab Dose 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erenumab+Dose+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T21:01:28.483Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02575833", "title": "Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stable Angina" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 89, "start_date": "2015-11-23", "completion_date": "2017-04-13", "has_results": true, "last_update_posted_date": "2018-08-24", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 8, "location_summary": "Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02575833" }, { "nct_id": "NCT02792517", "title": "Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Headache, Migraine" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Ethynil Estradiol/Norgestimate Oral Contraceptive", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 41, "start_date": "2016-02-12", "completion_date": "2016-09-09", "has_results": true, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 4, "location_summary": "Anaheim, California • Cypress, California • Dallas, Texas + 1 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02792517" }, { "nct_id": "NCT01952574", "title": "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Erenumab PFS", "type": "DRUG" }, { "name": "Erenumab AI/Pen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 483, "start_date": "2013-08-06", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Long Beach, California • National City, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01952574" }, { "nct_id": "NCT04417361", "title": "Galcanezumab for Vestibular Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vestibular Migraine" ], "interventions": [ { "name": "Galcanezumab Prefilled Syringe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2020-09-18", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04417361" }, { "nct_id": "NCT02456740", "title": "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 955, "start_date": "2015-07-17", "completion_date": "2017-06-19", "has_results": true, "last_update_posted_date": "2022-10-12", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 59, "location_summary": "Phoenix, Arizona • Anaheim, California • Encino, California + 55 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02456740" }, { "nct_id": "NCT03832998", "title": "Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab Dose 1", "type": "DRUG" }, { "name": "Erenumab Dose 2", "type": "DRUG" }, { "name": "Erenumab Dose 3", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 284, "start_date": "2019-09-05", "completion_date": "2026-01-07", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 38, "location_summary": "San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03832998" }, { "nct_id": "NCT05684692", "title": "Screening Trial for Pain Relief in Schwannomatosis (STARFISH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schwannomatosis", "Schwannomas", "Pain, Chronic" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Erenumab-Aooe", "type": "DRUG" }, { "name": "Siltuximab Matching Placebo", "type": "DRUG" }, { "name": "Erenumab-Aooe Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-08-31", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05684692" }, { "nct_id": "NCT03836040", "title": "Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab Dose 1", "type": "DRUG" }, { "name": "Erenumab Dose 2", "type": "DRUG" }, { "name": "Erenumab Dose 3", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 457, "start_date": "2019-07-19", "completion_date": "2026-11-19", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 38, "location_summary": "San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03836040" }, { "nct_id": "NCT02542605", "title": "To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Erenumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PACAP-38 Challenge Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 35, "start_date": "2015-11-11", "completion_date": "2017-11-08", "has_results": true, "last_update_posted_date": "2019-06-03", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 1, "location_summary": "Anaheim, California", "locations": [ { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542605" }, { "nct_id": "NCT04271202", "title": "Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Migraine" ], "interventions": [ { "name": "Emgality 120 MG in 1 ML Prefilled Syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2020-07-29", "completion_date": "2023-11-22", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-09-09T21:01:28.483Z", "location_count": 1, "location_summary": "Brookline, Massachusetts", "locations": [ { "city": "Brookline", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04271202" } ] }